Ovintiv Inc. (OVV) Stock Forecast
Data as of May 2, 2026Energy · Current price $60.64 (-1.45%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 9, 2026 | Josh Silverstein | UBS | $75.00 | +23.7% |
| Jan 17, 2026 | Lloyd Byrne | Jefferies | $54.00 | -10.9% |
| Oct 15, 2025 | Greg Pardy | RBC Capital | $55.00 | -9.3% |
| Aug 18, 2025 | Devin McDermott | Morgan Stanley | $48.00 | -20.8% |
| Apr 15, 2025 | Devin McDermott | Morgan Stanley | $50.00 | -17.5% |
| Jan 3, 2025 | Doug Leggate | Wolfe Research | $70.00 | +15.4% |
| Oct 28, 2024 | Neal Dingmann | Truist Financial | $47.00 | -22.5% |
| Oct 15, 2024 | Gabriele Sorbara | Williams Trading | $60.00 | -1.1% |
| Oct 1, 2024 | Roger Read | Wells Fargo | $42.00 | -30.7% |
| Sep 30, 2024 | Stephen Richardson | Evercore ISI | $54.00 | -10.9% |
| Jul 22, 2024 | Neal Dingmann | Truist Financial | $60.00 | -1.1% |
| Jul 17, 2024 | Doug Leggate | Wolfe Research | $65.00 | +7.2% |
| Jun 14, 2024 | Stephen Richardson | Evercore ISI | $60.00 | -1.1% |
| May 9, 2024 | Greg Pardy | RBC Capital | $62.00 | +2.2% |
| Apr 9, 2024 | Betty Jiang | Barclays | $69.00 | +13.8% |
| Apr 5, 2024 | Neal Dingmann | Truist Financial | $68.00 | +12.1% |
| Jun 16, 2022 | Travis Wood | National Bank | $115.00 | +89.6% |
| Jan 25, 2022 | Devin McDermott | Morgan Stanley | $49.00 | -19.2% |
| Jan 21, 2022 | Jeoffrey Lambujon | Tudor Pickering | $54.00 | -10.9% |
| Jan 13, 2022 | Jason Bouvier | Scotiabank | $46.00 | -24.1% |
Top Analysts Covering OVV
OVV vs Sector & Market
| Metric | OVV | Energy Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.19 | 2.54 | 2.41 |
| Analyst Count | 21 | 10 | 18 |
| Target Upside | -7.3% | +33.7% | +14.9% |
| P/E Ratio | 12.69 | 30.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.89B | $9.22B | $10.26B | 4 |
| 2027-03-31 | $2.00B | $2.22B | $2.52B | 1 |
| 2027-06-30 | $1.95B | $2.17B | $2.46B | 2 |
| 2027-09-30 | $1.99B | $2.20B | $2.50B | 2 |
| 2027-12-31 | $2.03B | $2.26B | $2.56B | 1 |
| 2028-03-31 | $2.20B | $2.44B | $2.77B | 1 |
| 2028-06-30 | $2.17B | $2.41B | $2.74B | 1 |
| 2028-09-30 | $2.19B | $2.44B | $2.77B | 1 |
| 2028-12-31 | $2.22B | $2.46B | $2.79B | 1 |
| 2029-12-31 | $8.09B | $8.98B | $9.77B | 1 |
| 2030-12-31 | $8.32B | $9.24B | $10.05B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.44 | $7.80 | $11.29 | 12 |
| 2027-03-31 | $1.73 | $1.99 | $2.34 | 4 |
| 2027-06-30 | $1.47 | $1.69 | $1.99 | 4 |
| 2027-09-30 | $1.57 | $1.81 | $2.13 | 4 |
| 2027-12-31 | $1.79 | $2.06 | $2.42 | 4 |
| 2028-03-31 | $2.17 | $2.49 | $2.92 | 5 |
| 2028-06-30 | $1.92 | $2.20 | $2.59 | 5 |
| 2028-09-30 | $2.07 | $2.37 | $2.79 | 5 |
| 2028-12-31 | $2.25 | $2.59 | $3.04 | 5 |
| 2029-12-31 | $6.41 | $7.37 | $8.20 | 1 |
| 2030-12-31 | $6.47 | $7.43 | $8.28 | 1 |
Frequently Asked Questions
What is the analyst consensus for OVV?
The consensus among 21 analysts covering Ovintiv Inc. (OVV) is Buy with an average price target of $54.50.
What is the highest price target for OVV?
The highest price target for OVV is $115.00, set by Travis Wood at National Bank on 2022-06-16.
What is the lowest price target for OVV?
The lowest price target for OVV is $32.00, set by Gabriel Daoud at Cowen & Co. on 2021-12-06.
How many analysts cover OVV?
21 analysts have issued ratings for Ovintiv Inc. in the past 12 months.
Is OVV a buy or sell right now?
Based on 21 analyst ratings, OVV has a consensus rating of Buy (2.19/5) with a -7.3% upside to the consensus target of $54.50.
What are the earnings estimates for OVV?
Analysts estimate OVV will report EPS of $7.80 for the period ending 2026-12-31, with revenue estimated at $9.22B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.